A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 May 2017
At a glance
- Drugs Buparlisib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Novartis
- 04 May 2017 Planned End Date changed from 28 Apr 2017 to 19 May 2017.
- 04 May 2017 Planned primary completion date changed from 28 Apr 2017 to 19 May 2017.
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 28 Apr 2017.